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Introduction
The centrosome nucleates and organizes microtubules in animal 
cells. It consists of a pair of cylindrically shaped centrioles sur-
rounded by fi  brous pericentriolar material. Before or during 
DNA replication in S phase, the centrioles split, and each cylin-
der serves as a template for the assembly of a new “daughter” 
centriole. Before mitosis, when cells contain two pairs of centri-
oles, each pair serves as a nucleation center for microtubules 
of the spindle apparatus. Defects in centrosome assembly or in 
centrosome separation can result in defective nucleation of spin-
dle microtubules, and in several cases, in the formation of mono-
polar spindles and mitotic arrest (Sunkel et al., 1995; Faragher 
and Fry, 2003). Several years ago, evidence was published that 
defective centrosome assembly can prevent cells from entering 
S phase. In particular, removal of the centrosome by microsurgery 
or by laser ablation resulted in a cell cycle arrest, as did inhibi-
tion or silencing of several centrosome-associated proteins, such 
as dynactin, PARP-3, centriolin, or AKAP450 (Hinchcliffe et al., 
2001; Khodjakov and Rieder, 2001; Quintyne and Schroer, 2002; 
Augustin et al., 2003; Gromley et al., 2003; Keryer et al., 2003). 
The mechanism leading to this centrosome-dependent cell cycle 
arrest in G1 phase has been unclear; it was proposed that a 
checkpoint control would prevent those cells with imperfect 
centrosomes from continuing the cell cycle, to prevent the as-
sembly of defective spindles later in mitosis (Murray, 2001).
In this study, we followed cell cycle progress after inhibition 
of centrosome assembly by depleting the pericentriolar proteins 
pericentriolar material 1 (PCM-1) and pericentrin. These proteins 
have been shown to be necessary for the assembly of other centro-
somal constituents (Dictenberg et al., 1998;   Dammermann and 
Merdes, 2002; Kubo and Tsukita, 2003). We found that depletion 
of PCM-1 or pericentrin activates the p38-dependent stress path-
way and the p53-dependent cell cycle checkpoint.
Results and discussion
We have previously shown that depletion of the protein PCM-1 
leads to defects in the assembly of the centrosomal components 
centrin, ninein, and pericentrin, and to an altered organization of 
the microtubule network in interphase cells (Dammermann and 
Merdes, 2002). To investigate the consequences of PCM-1 de-
pletion on the cell cycle, we performed RNA silencing experi-
ments in primary human fi  broblasts, MRC-5. After 72 h, PCM-1 
depletion was monitored by immunofl  uorescence (Fig. 1 A) and 
Western blotting (Fig. 2 A). Depleted cells were tested for incor-
poration of BrdU into the nucleus, as an indicator of DNA syn-
thesis (Fig. 1 B). We determined that in PCM-1–depleted cells 
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revious evidence has indicated that an intact cen-
trosome is essential for cell cycle progress and that 
elimination of the centrosome or depletion of individ-
ual centrosome proteins prevents the entry into S phase. 
To investigate the molecular mechanisms of centrosome-
  dependent cell cycle progress, we performed RNA silenc-
ing experiments of two centrosome-associated proteins, 
pericentriolar material 1 (PCM-1) and pericentrin, in pri-
mary human ﬁ  broblasts. We found that cells depleted of 
PCM-1 or pericentrin show lower levels of markers for 
S phase and cell proliferation, including cyclin A, Ki-67, 
proliferating cell nuclear antigen, minichromosome main-
tenance deﬁ  cient 3, and phosphorylated retinoblastoma 
protein. Also, the percentage of cells undergoing DNA 
replication was reduced by >50%. At the same time, lev-
els of p53 and p21 increased in these cells, and cells were 
predisposed to undergo senescence. Conversely, depletion 
of centrosome proteins in cells lacking p53 did not cause 
any cell cycle arrest. Inhibition of p38 mitogen-activated 
protein kinase rescued cell cycle activity after centrosome 
protein depletion, indicating that p53 is activated by the 
p38 stress pathway.
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only 15 ± 4% incorporated BrdU, as compared with 35 ± 3% in 
controls, as expected for a normal cycling population (Fig. 1 B). 
This is consistent with previous reports on microinjection of 
PCM-1–inhibiting antibodies (Balczon et al., 2002) and on cen-
trosome removal by microsurgery or laser ablation, which pre-
vent cells from entering S phase (Hinchcliffe et al., 2001; 
Khodjakov and Rieder, 2001). Several years ago, experiments on 
cells treated with the microtubule drugs colcemid, nocodazole, 
and taxol indicated that untransformed cells are arrested in G1 
phase, when microtubules are depolymerized or when micro-
tubule dynamics are altered (Trielli et al., 1996; Di Leonardo 
et al., 1997; Lanni and Jacks, 1998). This raises the question of 
whether DNA replication in PCM-1–depleted cells is inhibited 
because of an altered microtubule network, or whether defects at 
the centrosome itself suffi  ce to induce a cell cycle arrest. There-
fore, we depleted a second centrosome protein, pericentrin (Fig. 
1 A), which in contrast to PCM-1, only slightly reduces micro-
tubule density but seems to have no signifi  cant effect on micro-
tubule anchoring at the centrosome (Dammermann and Merdes, 
2002). Consistently, depletion of pericentrin also led to a reduc-
tion of BrdU incorporation (Fig. 1 B).
Because these data indicated that cells failed to undergo S 
phase–dependent DNA replication when missing the full com-
plement of centrosome proteins, we wanted to test in more de-
tail at what stage cells are arrested. Immunoblotting of cell 
extracts of PCM-1–depleted cultures indicated drastic reduction 
of cyclin A (Fig. 2 A), which is normally found expressed in 
cells during late G1, S, and G2 phases. Furthermore, we de-
tected that PCM-1–depleted cells also showed reduced amounts 
of the proteins minichromosome maintenance defi  cient  3 
(MCM3) and proliferating cell nuclear antigen (PCNA) acting 
in licensing and DNA replication (Fig. 2 A) and reduced per-
centages of cells expressing the cell proliferation marker Ki-67 
(Fig. 2 C). Equivalent data were also obtained by depletion of 
pericentrin (Fig. 2 B). Altogether, these data indicated that de-
pletion of centrosome proteins reduces the number of cells en-
tering S phase. We verifi  ed this hypothesis by comparing profi  les 
of cell cultures analyzed by fl  ow cytometry (Fig. 2 D): consis-
tent with our data on BrdU incorporation, PCM-1–depleted 
cells showed a reduction of S phases from 28 to 15%.
Figure 1.  Depletion of PCM-1 and pericentrin prevents DNA replication. 
(A) Immunoﬂ  uorescence of MRC-5 ﬁ  broblasts treated with control RNA or 
siRNA against PCM-1 and pericentrin, respectively. Bar, 10 μm. Graphs 
depict the percentages of cells lacking PCM-1 or pericentrin expression 
  after treatment with control or silencing RNAs. Cells were scored as negative 
if they lacked centrosomal staining of PCM-1 or pericentrin, only display-
ing diffuse background ﬂ  uorescence. (B) Percentages of cells incorporating 
BrdU after treatment with control RNA or silencing RNA against PCM-1 or 
pericentrin. Data were obtained from cell cultures that were double labeled 
for BrdU and PCM-1 or pericentrin. Among cell cultures treated with silenc-
ing RNA, only cells that were visibly depleted of PCM-1 or pericentrin were 
scored. Error bars indicate SD.
Figure 2.  Depletion of PCM-1 leads to cell cycle arrest in G1 or G0 phase. 
(A) Immunoblots of MRC-5 cells treated with control RNA or siRNA against 
PCM-1, pRb, or both PCM-1 and pRb simultaneously. Blots were probed 
with antibodies against PCM-1, cyclin A, the licensing factor MCM3, the 
DNA replication factor PCNA, pRb, and α-tubulin. (B) Immunoblots of cells 
treated with control RNA or siRNAs against PCM-1, pericentrin, or both 
  simultaneously. Blots were probed with antibodies against MCM3, pRb, and 
α-tubulin. Arrowheads in A and B indicate migration positions of hyper- 
and hypophosphorylated pRb. (C) MRC-5 cells treated with control RNA, 
siRNA against PCM-1, or siRNA against PCM-1 and pRb simultaneously. 
The percentages of cells staining positively for the proliferation marker 
Ki-67 or for incorporated BrdU are shown. Experimental conditions were 
similar to Fig. 1 B. Error bars indicate SD. (D) Flow-cytometric analysis of 
MRC-5 cells treated with control RNA or siRNA against PCM-1. (E) Immuno-
blots of MRC-5 cells treated with control RNA or siRNA against PCM-1 for 
48 or 120 h or with siRNA against pericentrin for 72 h. Blots were probed 
with antibodies against p53, α-tubulin, or p21.CENTROSOME-DEPENDENT CELL CYCLE ARREST • SRSEN ET AL. 627
We then wanted to determine whether S phase entry was 
blocked because of checkpoint activation in cells depleted of 
PCM-1 or pericentrin. We found that the overall levels of the 
retinoblastoma protein (pRb) were reduced to 38 ± 17% and 
that most of the remaining pRb, normally hyperphosphorylated 
during late G1 and S phase, was present in its faster migrating, 
hypophosphorylated form (77 ± 13% in depleted vs. 38 ± 13% 
in control cells; Fig. 2, A and B). The checkpoint protein p53, 
however, was found up-regulated, especially after prolonged 
depletion of PCM-1 or pericentrin (Fig. 2 E). In depleted cells, 
the Cdk2 inhibitor p21 was found equally up-regulated (Fig. 2 E). 
These data suggested that depletion of the two centrosome-
  associated proteins PCM-1 and pericentrin leads to the activa-
tion of the p53-dependent checkpoint.
In the next step, we wanted to determine whether cell cy-
cle progress would be affected if the p53-dependent checkpoint 
control was abrogated. For this purpose, we attempted simulta-
neous depletion of p53 and PCM-1 by cotransfecting siRNA 
oligomers against both. Fig. 3 A shows that p53 levels could not 
be reduced when PCM-1 was missing. We tried to refi  ne this 
experiment by sequential depletion of MRC-5 cells, by fi  rst de-
pleting  >90% of p53 after 72 h, followed by simultaneous 
siRNA treatment against p53 and PCM-1. However, we ob-
served that under these conditions, p53 levels increased back 
to 40–50% in three different experiments (unpublished data). 
We concluded that p53 turnover is altered and that the residual 
p53 protein might be stabilized in the absence of an intact cen-
trosome. We therefore changed our experimental strategy and com-
pared cell cycle progress after PCM-1 depletion in several cell 
lines lacking p53. We used mouse embryonic fi  broblasts from 
p53 knockout mice (unpublished data) as well as the human 
lung carcinoma cell line H1299. Because of the loss of p53 
checkpoint control, both lines displayed a relatively high basic 
rate of DNA synthesis (Fig. 3 B). We found that in both p53−/− 
cell lines, PCM-1 depletion did not inhibit cell cycle progress. 
The levels of PCNA, MCM3, and hyperphosphorylated pRb re-
mained high (Fig. 3, B and C, H1299). In addition, we also 
tested the effect of PCM-1 depletion in the p53+/+ and p53−/− 
lines of HCT116 cells. Unfortunately, only 30% of these cells 
showed lower PCM-1 levels. BrdU incorporation in these was 
reduced from 42% in controls to 33% in partially depleted p53+ 
cells, whereas p53− cells showed BrdU incorporation in 49% 
after partial PCM-1 depletion. Consistently, HeLa cells with 
functionally suppressed p53 checkpoint control do not arrest in 
the absence of centrosomes (La Terra et al., 2005). In contrast to 
p53, the removal of pRb did not cause resumption of the cell 
cycle in PCM-1–depleted MRC-5 cells, because the percent-
ages of BrdU-incorporating cells and Ki-67–expressing cells 
remained low, as did the expression of MCM3 protein (Fig. 2, 
A and C). On the other hand, the amounts of cyclin A and PCNA 
were restored to nearly control levels. A possible scenario would 
be that centrosome defects activate both pRb and p53 in paral-
lel, with p53 having feedback effects on pRb phosphorylation 
and pRb protein levels but not vice versa. This would be consis-
tent with our observation that pRb levels drop after PCM-1 or 
pericentrin depletion and that depletion of pRb itself does not 
fully restore S phase activity, which is probably blocked be-
cause of checkpoint control mechanisms directly dependent on 
p53. Eventually, loss of pRb might be compensated by Rb-
  related “pocket proteins,” such as p107 or p130.
Finally, we addressed the question of how defects in cen-
trosome assembly could activate the p53-dependent check-
point. It has been reported that p38 MAPK is involved in the 
cell’s response to a range of stress factors, such as UV irradia-
tion, osmotic shock, heat shock, starvation, and cytokine treat-
ment (Zarubin and Han, 2005). The response to these stress 
factors is mediated partly through p53 phosphorylation, which 
is believed to stabilize p53 and to increase the expression of the 
Cdk inhibitor p21, thereby blocking the cell cycle (Agarwal 
et al., 1998). To assess the involvement of stress-activated p38 
MAPK in response to centrosome defects, we have treated 
PCM-depleted MRC-5 cells with the p38 MAPK–specifi  c in-
hibitor SB203580. This inhibitor blocks p38 activity but affects 
neither p38 protein levels nor p38 phosphorylation. We found 
that the inhibitor prevented cell cycle arrest, as indicated by re-
sumption of DNA synthesis (Fig. 4 B). p38 inhibition in PCM-1–
depleted cells also restored regular levels of cyclin A and 
hyperphosphorylated pRb, as well as expression of Ki-67 and 
MCM3 (Fig. 4). Further, the inhibition of p38 led to decreased 
levels of p21 but only slightly decreased p53 (Fig. 4 A). This 
could be explained by a stabilization of p53 after centrosome 
inactivation, as discussed in the previous paragraph, which 
might occur independently of p38-dependent p53 activation. 
Alternatively, the centrosome-dependent cell cycle arrest might 
not simply be a linear consequence of p53 activation via p38. 
For example, p53 might be activated by other kinases in addi-
tion to p38. Moreover, although p38 has been shown in multi-
ple experiments to mediate cell cycle arrest by phosphorylating 
Figure 3.  Cell cycle arrest after PCM-1 depletion depends on the check-
point protein p53. (A) Immunoblots of MRC-5 cells treated with control RNA 
or siRNAs against PCM-1, p53, or both PCM-1 and p53 combined. Blots 
were probed with antibodies against p53, PCM-1, or α-tubulin. (B) Graph 
depicts BrdU incorporation in p53−/− H1299 cells treated with control 
RNA or siRNA against PCM-1. Error bars indicate SD. (C) Immunoblots of 
H1299 and MRC-5 cells treated with control RNA or siRNA against PCM-1 
(PCM1d) for 72 h. Blots were probed with antibodies against PCM-1, p53, 
PCNA, MCM3, pRb, or α-tubulin.JCB • VOLUME 174 • NUMBER 5 • 2006  628
various sites of p53 (Bulavin et al., 1999; Huang et al., 1999), 
p38 is also known to phosphorylate and thereby inactivate 
Cdc25A and cyclin D, which in turn arrests the cell cycle 
(Lavoie et al., 1996; Casanovas et al., 2000; Goloudina et al., 
2003; Khaled et al., 2005). However, p38 MAPK activation in 
the absence of p53 seems to be insuffi  cient for centrosome-
  dependent cell cycle arrest because PCM-1 depletion in 
p53−/− cells did not stop the cell cycle.
In our PCM-1–depletion experiments, we observed a sig-
nifi  cant decrease in the expression of proteins associated with 
cell proliferation, such as MCM3, PCNA, or Ki67. However, 
because about half of the depleted cells were still entering 
S phase, we wanted to test whether centrosome defects only 
slowed down cell cycle activity, or whether depleted cells were 
predisposed to a stable arrest that did not affect all cells simul-
taneously. Immunofl  uorescence of p53 after PCM-1 depletion 
revealed that p53 levels varied between individual cells, with 
some cells showing a very high increase but a small increase 
or no obvious response in others (Fig. 5 A). We then tested 
whether the cells’ response to centrosome inhibition induces 
exit from the cell cycle via senescence. Senescence is marked 
by the   acquisition of a permanent G0 state and an increase of 
cellular β-galactosidase activity (Dimri et al., 1995). A cyto-
chemical analysis of PCM-1–depleted cultures revealed a 
10-fold   increase of β-galactosidase–positive cells (Fig. 5 B), 
compared with a basal level of 3% in controls. Consistently, 
we previously reported that cultures of U2OS cells died af-
ter silencing of PCM-1 for long periods (Dammermann and 
Merdes, 2002), although the experimental conditions varied 
from the protocol used here. Senescence has been character-
ized as a cellular program activated as a result of physiological 
stresses preventing further cell proliferation (Ben-Porath and 
Weinberg, 2004).   Instead of a specifi  c centrosome-dependent 
cell cycle control as proposed by Murray (2001), we propose 
a stress-driven response to centrosome defects. The idea of the 
centrosome as a center for stress-related signaling seems plau-
sible, considering its central location in the focus of the mi-
crotubule network and its ability to bind various molecules of 
signaling pathways and of cell cycle regulation. For example, 
signifi  cant amounts of protein kinase A, polo-like kinase, and 
protein phosphatases 1 and 2A, as well as cyclin E and p53, 
have all been localized to the centrosome (Fry et al., 2000; 
Morris et al., 2000;   Matsumoto and Maller, 2004). Their local-
ization and anchoring is mediated by large coiled-coil proteins 
Figure 4.  Inhibition of the stress kinase p38 MAPK prevents cell cycle 
  arrest after PCM-1 depletion. (A) Immunoblots of MRC-5 cells treated with 
control RNA, siRNA against PCM-1, or siRNA against PCM-1 together with 
the p38 inhibitor SB203580 (PCM-1 + INH). Blots were probed with anti-
bodies against pRb, cyclin A (cyc A), p53, the Cdk inhibitor p21, active 
p38, or α-tubulin. (B) Graphs depicting MRC-5 cells treated with control 
RNA, siRNA against PCM-1, or siRNA against PCM-1 together with the 
p38 inhibitor SB203580 (PCM-1 + INH). The staining of BrdU incorpora-
tion (after RNA treatment for 72 or 96 h), Ki-67 immunoﬂ  uorescence (after 
RNA treatment for 96 h), or MCM3 immunoﬂ  uorescence (after RNA treat-
ment for 72 h) is shown.
Figure 5.  PCM-1–depleted cells are predisposed to exit from the cell 
cycle and to undergo senescence. (A) Fibroblasts treated with control and 
PCM-1 siRNA, stained for PCM-1 (red), DNA (blue), and p53 (green). 
(B) β-Galactosidase assay on control and PCM-1–depleted cells 96 h after 
transfection using 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside as a 
chromogenic substrate. Bars, 10 μm.CENTROSOME-DEPENDENT CELL CYCLE ARREST • SRSEN ET AL. 629
such as   pericentrin, AKAP450, or AKAP220 (Diviani et al., 
2000; Reinton et al., 2000; Diviani and Scott, 2001). Absence 
or inhibition of anchoring proteins could therefore disrupt cel-
lular signaling pathways and elicit a stress response. Further re-
search will be necessary to investigate the multiple interactions 
between centrosome proteins, cell signaling, and the complex 
regulation of the cell cycle.
Materials and methods
Cell culture and transfection experiments
Human fetal lung ﬁ  broblasts MRC-5 (European Collection of Cell Cultures) 
and H1299 cells (a gift from B. Vojtesek, Masaryk Memorial Cancer Insti-
tute, Brno, Czech Republic) were cultured in DME (Invitrogen), supple-
mented with 10% fetal bovine serum (Perbio Science), 2 mM L-glutamine, 
and antibiotics. HCT116 cells (a gift from B. Vogelstein, Johns Hopkins 
University, Baltimore, MD) were cultured in McCoy’s medium containing 
the same supplements. The cells were plated to reach 80% conﬂ  uency at 
the time of transfection. About 3 × 10
6 cells from early passages of MRC-5 
and 0.5 × 10
6 cells of H1299 or HCT116 were transfected with 9 or 
18 μg of siRNA oligonucleotides, respectively, in a Nucleofector electro-
poration device, using the appropriate transfection kit (Amaxa). The cells 
were then plated onto two 10-cm Petri dishes to obtain a conﬂ  uency of 
 30–40% on the next day. Routinely, siRNA treatment was for a total of 
72 h before ﬁ  xation or preparation of cell extracts, unless indicated otherwise. 
P38 MAPK inhibition was performed in cells that were transfected with 
  oligos and cultured overnight before the speciﬁ   c inhibitor SB203580 
  (Calbiochem) was added at a concentration of 10 μM. Inhibitor-treated 
cells were left in culture for another 48 h and then ﬁ  xed in methanol or 
  extracted for SDS-PAGE.
Antibodies and siRNA oligonucleotides
Cells were harvested using trypsin-EDTA, counted, and washed in ice-cold 
PBS. Cells were extracted in SDS-PAGE sample buffer and boiled for 6 min. 
Amounts of extract equal to 200,000 cells were loaded and run on 7.5, 
10, or 12.5% SDS-PAGE gels and blotted onto nitrocellulose. The following 
antibodies were used for Western blot analysis or immunoﬂ  uorescence: 
  afﬁ  nity-puriﬁ   ed rabbit anti–PCM-1 (Dammermann and Merdes, 2002), 
anti-MCM3 mAb clone 3A2 (MBL International Corporation), anti-pRB mAb 
clone 4H1 (Cell Signaling), anti-PCNA mAb clone PC-10 (Sigma-  Aldrich), 
anti–cyclin E mAb clone HE12 (Zymed Laboratories), anti–cyclin A mAb 
clone Cy-A1 (Sigma-Aldrich), anti p53 mAb clone DO-1 (Novocastra), 
anti-p21 mAb clone SX118 (BD Biosciences), rabbit anti-ACTIVEp38MAPK 
polyclonal antibody (Promega), anti–α-tubulin mAb clone DM1A (Sigma-
  Aldrich), goat anti–mouse polyclonal antibody HRP (Promega), donkey anti–
rabbit IgG polyclonal antibody HRP (GE Healthcare), rat anti-BrdU mAb 
(Harlan), anti–Ki-67 mAb clone MM1 (Novocastra), rabbit anti-  pericentrin 
polyclonal antibody (Covance), donkey anti–rabbit or anti–mouse IgG con-
jugated with Alexa 488 or Alexa 594 (Invitrogen). Quantiﬁ  cation of pro-
tein levels was performed by scanning immunoblots and analyzed using 
the Photoshop (Adobe) histogram tool. Quantiﬁ  cation of cells expressing 
speciﬁ  c proteins was performed by counting siRNA-treated cells that were 
double stained with PCM-1 antibodies to verify depletion. The following 
siRNA oligomers with dTdT overhangs (QIAGEN) were used: PCM-1.2, 
corresponding to human PCM-1 (U  C  A  G  C  U  U  C  G  U  G  A  U  U  C  U  C  A  G  ); peric, 
corresponding to human pericentrin (G  C  A  G  C  U  G  A  G  C  U  G  A  A  G  G  A  G  A  ; 
Dammermann and Merdes, 2002); pRB (G  C  C  C  U  U  A  C  A  A  G  U  U  U  C  C  U  A  G  ); 
and p53 (C  U  A  C  U  U  C  C  U  G  A  A  A  A  C  A  A  C  G  ).
Flow cytometry analysis
All cells in a culture dish were harvested by trypsinization, washed in ice-
cold PBS, and ﬁ  xed in 80% ice-cold ethanol in PBS. Before staining, the 
cells were spun down in a cooled centrifuge and resuspended in the cold. 
Bovine pancreatic RNase (Sigma-Aldrich) was added at a ﬁ  nal concentra-
tion of 2 μg/ml, and cells were incubated at 37°C for 30 min, followed by 
an incubation in 20 μg/ml of propidium iodide (Sigma-Aldrich) for 20 min 
at room temperature. 10,000 cells were analyzed on a ﬂ  ow cytometer 
(FACSCalibur; BD Biosciences).
𝗃-Galactosidase assay
β-Galactosidase staining at pH 6.0 was performed as described in Dimri 
et al. (1995).
Immunoﬂ  uorescence microscopy
Cells grown on coverslips were ﬁ  xed in ice-cold methanol and stored at 
−20°C until use. Antibody staining was performed using the reagents 
listed in the previous paragraphs, according to standard protocols. The 
percentage of cells in S phase was assessed by adding 100 μM BrdU 
(Sigma-Aldrich) to the cultures 30 min before ﬁ  xation. Double labeling of 
BrdU and PCM-1 was performed by probing ﬁ  rst for PCM-1, using rabbit 
anti–PCM-1 and ﬂ   uorescent anti-rabbit antibody, and coverslips were 
postﬁ  xed in PBS containing 3.7% paraformaldehyde, treated with 2 M 
HCl for 30 min, and stained with rat anti-BrdU and ﬂ  uorescent secondary 
anti-rat antibody. Cells were viewed with a ﬂ   uorescence microscope 
  (Axioskop 2; Carl Zeiss MicroImaging, Inc.) equipped with a camera 
  (Axiocam; Carl Zeiss MicroImaging, Inc.) and software (Axiovision; Carl 
Zeiss MicroImaging, Inc.). The images were imported into Photoshop 
for presentation.
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